InvestorNewsBreaks – Processa Pharmaceuticals Inc.’s (NASDAQ: PCSA) IND Application for Phase 2 Clinical Trial of NGC-Cap in Patients with Breast Cancer Receives FDA Clearance
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced that it has received approval from the U.S. Food and Drug Administration (“FDA”) for its Investigational New Drug (“IND”) application for its lead product candidate, Next Generation Capecitabine (“NGC-Cap”). According to the announcement, the FDA clearance enables the commencement of a…